SCHEMBL4134032

SCHEMBL4134032

CC(C)c1ccc(C2(C)CCCc3c(N4CCNCC4)nc(N)nc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 18/20 0.46
HRH3 Q9Y5N1 8/20 0.41
KCNH2 Q12809 2/20 0.36
ADRB1 P08588 1/20 0.34
TACR2 P21452 1/20 0.34
ADRA1D P25100 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
CCR1 P32246 1/20 0.34
HRH1 P35367 1/20 0.34
AVPR1A P37288 1/20 0.34
HTR2B P41595 1/20 0.34
HTR3A P46098 1/20 0.34
SIGMAR1 Q99720 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4134476 0.87 HRH4 (0.55) HRH4HRH3KCNH2
SCHEMBL4125137 0.85 HRH4 (0.51) HRH4HRH3KCNH2HRH1
SCHEMBL4118873 0.84 HRH4 (0.50) HRH4HRH3KCNH2HTR3ASIGMAR1
SCHEMBL4133798 0.84 HRH4 (0.45) HRH4HRH3KCNH2HTR2C
SCHEMBL4129610 0.84 HRH4 (0.54) HRH4HRH3KCNH2
SCHEMBL4124018 0.82 HRH4 (0.49) HRH4HRH3KCNH2HTR3ASIGMAR1
SCHEMBL4128029 0.80 HRH4 (0.49) HRH4HRH3KCNH2ADRB1
SCHEMBL4115970 0.79 HRH4 (0.43) HRH4HRH3KCNH2ADRB1HTR2C
SCHEMBL4115636 0.78 HRH4 (0.47) HRH4HRH3HTR2C
SCHEMBL4129414 0.78 HRH4 (0.43) HRH4HRH3KCNH2ADRB1TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH4 3370/4885HRH3 3555/4885KCNH2 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.